Rheumatology Therapeutics Market is thriving worldwide by 2029

Rheumatology Therapeutics market is anticipated to grow at a CAGR of 3.2% during the forecast period (2023-2030). Therapeutic drugs are used to slow down the progression of certain autoimmune rheumatic diseases such as rheumatic arthritis (RA). The increasing prevalence of RA globally has bolstered the launch of novel therapeutic agents and favorable refurbishment policies for high-cost treatment products are some of the factors driving the market growth. According to the National Institute of Health (NIH), in May 2023, rheumatic arthritis is more prevalent in women compared to men, with a lifetime risk of rheumatic arthritis of 3.6% in women compared to 1.7% in men. RA risk also increases with age, with a peak incidence between age 65 to 80 years of age. Furthermore, the rise in the rate of launches of novel biologics drugs, increasing approvals and growing penetration of generic drugs extend profitable opportunities to the rheumatology therapeutics market. For instance, in June 2022, Amgen announced that FDA approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

Get Free Sample link @ https://www.omrglobal.com/request-sample/rheumatology-therapeutics-market

The global rheumatology therapeutics market is segmented on the drug type, disease indication, category, and distribution channel. Based on the drug type, the market is sub-segmented into disease-modifying anti-rheumatic drugs, nonsteroidal anti-inflammatory drugs, corticosteroids, uric acid drugs and others. Based on the disease indication, the market is sub-segmented into rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, and ankylosing spondylitis. Based on the category, the market is bifurcated into prescription and OTC. Furthermore, on the basis of distribution channel, the market is sub-segmented into hospital pharmacy, retail pharmacy and online pharmacy. Among the disease indication, the rheumatoid arthritis sub-segment is anticipated to hold a considerable share of the market owing to the development of novel technologies such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-based genome editing, RNA interference, PROTACs (proteolysis-targeted chimeras), and artificial intelligence (AI)-based drug design enable the screening of therapies targeting.

full report of Rheumatology Therapeutics Market available @ https://www.omrglobal.com/industry-reports/rheumatology-therapeutics-market

  • Market Coverage
  • Market number available for – 2023-2029
  • Base year- 2022
  • Forecast period- 2023-2029
  • Segment Covered- By Source, By Product Type, By Applications
  • Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill
  • , and others

Market Segmentation

Global Rheumatology Therapeutics Market by Drug Type

  • Disease-Modifying Anti-Rheumatic Drugs
  • Non-Steroidal Anti-Inflammatory Drugs
  • Corticosteroids
  • Uric Acid Drugs
  • Others

Global Rheumatology Therapeutics Market by Disease Indication

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Gout
  • Psoriatic Arthritis
  • Ankylosing Spondylitis

Global Rheumatology Therapeutics Market by Category

  • Prescription
  • Over-the-Counter (OTC)

Global Rheumatology Therapeutics Market by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Regional Analysis

  • North America
  • United States
  • Canada
  • Europe
  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
  • Rest of the World

Company Profiles 

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Aurinia Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Eli Lilly
  • Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Private Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi, Genentech, Inc.
  • Takeda Pharmaceutical Company Ltd.
  • UCB S.A.

The Report Covers

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global rheumatology therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/rheumatology-therapeutics-market

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 780-304-0404